New Antibiotic: Tigecycline

[Guest guest]

....a semi synthetic glycylcycline derived from the minocycline

molecule. Tigecycline has documented activity against tetracycline-

resistant gram-positive and gram-negative pathogens refractory by

both efflux and ribosomal protection mechanisms. ...

* * * * * * * * * * * * * * * * * * * * * * * * * * *

MYCOPLASMA REGISTRY

for gulf war syndrome & chronic fatigue syndrome

© Dudley & Leslee Dudley 2005. All rights reserved.

MycoplasmaRegistry/

Our FREE Brochure: " How to Get an Accurate Polymerase Chain Reaction

(PRC) Blood Test for Mycoplasmal and Other Infections-with a List

of International Laboratories " © by and Leslee Dudley is sent

automatically and immediately to all new subscribers. It is updated

with current information and the new version is posted to the

Mycoplasma Registry Reports & News list each month.

MycoplasmaRegistry-subscribe

* * * * * * * * * * * * * * * * * * * * * * * * * * *

Tigecycline data reveals MRSA efficacy

Drug Researcher.com - Montpellier,France - April 4, 2005

http://www.drugresearcher.com/news/printNewsBis.asp?id=59187

05/04/2005 - Data from the first drug in a new class of antibiotics

was presented at this year's ECCMID conference, which showed the drug

demonstrated its efficacy against a wide variety of gram-positive and

gram-negative bacteria including multi-drug-resistant bugs.

Data presented at the show demonstrated that tigecycline monotherapy

exhibited antibiotic activity against a wide range of bacteria

commonly found in patients hospitalised in intensive care units

worldwide including Staphylococcus aureus, Acinetobacter spp, and

Klebsiella. The data, presented at the European Congress of Clinical

Microbiology and Infectious Diseases (ECCMID), represents an

importance on many different levels. As experts warn that `the world

may be running out of effective antibiotics,' statistics from

pharmaceutical companies reveal that few new antibiotics have been

developed in the last 20 years and there are very few in the pipeline

currently.

The problem of growing resistance means that new broad-spectrum

options are essential in the fight against MRSA and other hospital

acquired infections

Tigecycline is a semi synthetic glycylcycline derived from the

minocycline molecule. Tigecycline has documented activity against

tetracycline-resistant gram-positive and gram-negative pathogens

refractory by both efflux and ribosomal protection mechanisms.

Its mode of action on bacterial ribosomes shows identical and

overlapping binding sites when compared to tetracycline, but the

position 9 substitution of tigecycline provides additional steric

hindrance features and resulting greater spectrum of activity.

Wyeth filed the submission for global regulatory approval for

tigecycline at the end of last year (16th Dec 2004) with the FDA,

EMEA and authorities in Canada and Australia. Approval is sought for

tigecycline as a monotherapy to treat patients with complicated intra-

abdominal infections (cIAI) and complicated skin and skin structural

infections (cSSSI) caused by gram-negative and gram-positive

pathogens, anaerobes and both methicillin susceptive and methicillin

resistant strains of Staphylococcus aureus (MSSA and MRSA).

The urgent need for new antibiotic treatments has led to the FDA

designating tigecycline priority review status. This status can only

be given to those drugs, which if approved, would be a significant

improvement compared with existing treatments.

According to a recent National Audit report from the UK MRSA rates

are rising dramatically across Europe with the UK, Eire, Greece and

Italy having the highest rates. Within these the proportion of MRSA

rates is highest among patients admitted to intensive care units.

Patients hospitalised in the intensive care unit (ICU) are at

particular risk for acquiring nososcomial infections. Exposure to

various antimicrobial agents may further complicate such

hospitalisation and create conditions that favour resistance

selection among host bacterial flora or nosocomially transmitted

pathogens. Thus, rates of antimicrobial resistance are generally

higher in bacteria isolated from ICUs compared with other hospital

wards and outpatient clinics

The prevalence of nosocomial infections caused by MRSA has been

increasing for several years in many countries around the world. The

US Centres for Disease Control and Prevention estimates that between

60,000 and 80,000 Americans die each year from nosocomial infections

and the cause in the majority of cases is S. aureus.

Reports from the UK National Audit Office state that at any one time,

9 per cent of NHS hospital patients are suffering from an infection

such as MRSA, acquired whilst in surgery or as an inpatient on the

hospital wards. These `nosocomial' infections affect 100,000 people

annually, costing the National Health Service £1 billion (€1.5bn),

and causing up to 5,000 deaths.

© 2000/2005–NOVIS. – .

* * * * * * * * * * * * * * * * * * * * * * * * * * *

NOTE: In accordance with Title 17 U.S.C. Section 107, this material is

distributed without profit to those who have expressed a prior

interest in receiving the included information for research and

educational purposes. The Mycoplasma Registry has no affiliation

with the originator of this article nor is the Mycoplasma Registry

endorsed or sponsored by the originator. If you wish to use

copyrighted material from this site for purposes of your own that go

beyond 'fair use', you must obtain permission from the copyright

owner.

* * * * * * * * * * * * * * * * * * * * * * * * * * *